// App-Quantinova.ai

: Real-world evidence in patient-related outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate plus prednisone (AA+P).

Researchers

Presenter

  • Geoffrey Gotto

Principal Investigators

  • Vincent Fradet

  • Darrel Drachenberg

  • Robert Sabbagh

  • Ricardo A. Rendon

  • Bobby Shayegan

  • Brita Lavender Danielson

  • Richard Casey

  • Katherine Chan

  • Fernando Camacho

  • Anousheh Zardan

  • Huong Hew

  • Andrew Feifer

Medical Centers

  • University of Calgary, Calgary, AB, Canada

  • CHUQ Hotel-Dieu de Quebec, Quebec City, QC, Canada

  • Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada

  • Universite de Sherbrooke, Sherbrooke, QC, Canada

  • Dalhousie University, Halifax, Nova Scotia, Canada.

  • Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada

  • University of Alberta, Edmonton, AB, Canada

  • The Fe/Male Health Centre, Oakville, ON, Canada

  • Janssen Inc., Toronto, ON, Canada

  • Janssen Inc., Toronto, ON, Canada

  • Medical Affairs, Janssen Inc., Toronto, ON, Canada

  • Trillium Health Centre, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Prednisone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02364531

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved